PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition

Neurobiology of Aging

Volumn 33, Issue 11, 2012, Pages 2561-2571

  Poisnel, Géraldine ^a   Dhilly, Martine ^a   Moustié, Olivier ^a   Delamare, Jérôme ^a   Abbas, Ahmed ^a   Guilloteau, Denis ^b   Barré, Louisa ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

amyloid plaques; 18F AV45; Alzheimer's pathology; APP PS1 21 murine model; Autoradiography; PET imaging

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AV 45; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; PRESENILIN; PRESENILIN 1 21; THIOFLAVINE; UNCLASSIFIED DRUG;

AGING; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIOACCUMULATION; BRAIN CORTEX; BRAIN RADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG UPTAKE; EX VIVO STUDY; FEMALE; HIPPOCAMPUS; IN VIVO STUDY; ISOTOPE LABELING; LONGITUDINAL STUDY; MICRORADIOGRAPHY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AUTORADIOGRAPHY; DISEASE MODELS, ANIMAL; FEMALE; FLUORODEOXYGLUCOSE F18; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84865590071     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.12.024     Document Type: Article

References (57)

1. Bacskai B.J., Hickey G.A., Skoch J., Kajdasz S.T., Wang Y., Huang G.F., Mathis C.A., Klunk W.E., Hyman B.T. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12462-12467.
2. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113.
3. Blanchard V., Moussaoui S., Czech C., Touchet N., Bonici B., Planche M., Canton T., Jedidi I., Gohin M., Wirths O., Bayer T.A., Langui D., Duyckaerts C., Tremp G., Pradier L. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice. Exp. Neurol 2003, 184:247-263.
4. Bourasset F., Mélissa O., Tremblay C., Julien C., Do T.M., Oddo S., Laferla F., Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 2009, 56:808-813.
5. Chamberlain R., Wengenack T.M., Poduslo J.F., Garwood M., Jack C.R. Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr. Med. Imaging Rev 2011, 7:3-7.
6. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., Benedum T.E., Kilbourn M.R., Skovronsky D., Kung H.F. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med 2009, 50:1887-1894.
7. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., Pontecorvo M.J., Hefti F., Carpenter A.P., Flitter M.L., Krautkramer M.J., Kung H.F., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Reiman E.P., Reiman P.E., Zehntner S.P., Skovronsky D.M. Use of Florbetapir-PET for Imaging β-Amyloid Pathology. JAMA 2011, 305:275-283. AV45-A07 Study Group.
8. Constantinescu C.C., Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys. Med. Biol 2009, 54:2885-2899.
9. Delatour B., Epelbaum S., Petiet A., Dhenain M. In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?. Int. J. Alzheimers Dis 2010, pii: 604853.
10. Dhenain M., El Tannir El Tayara N., Wu T.D., Guégan M., Volk A., Quintana C., Delatour B. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol. Aging 2009, 30:41-53.
11. Dubois B., Feldman H.H., Jacova C., Cummings J.L., DeKosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
12. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115:5-38.
13. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., Brooks D.J. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
14. Faure A., Verret L., Bozon B., El Tannir El Tayara N., Ly M., Kober F., Dhenain M., Rampon C., Delatour B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol. Aging 2011, 32:407-418.
15. Gandy S., Simon A.J., Steele J.W., Lublin A.L., Lah J.J., Walker L.C., Levey A.I., Krafft G.A., Levy E., Checler F., Glabe C., Bilker W.B., Abel T., Schmeidler J., Ehrlich M.E. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann. Neurol 2010, 68:220-230.
16. Gründer G. "Absolute" or "relative": choosing the right outcome measure in neuroimaging. Neuroimage 2009, 45:258-259.
17. Hemming M.L., Selkoe D.J. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem 2005, 280:37644-37650.
18. Higuchi M., Maeda J., Ji B., Maruyama M., Okauchi T., Tokunaga M., Ono M., Suhara T. In vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. Biochim. Biophys. Acta 2010, 1802:373-388.
19. Hintersteiner M., Enz A., Frey P., Jaton A.L., Kinzy W., Kneuer R., Neumann U., Rudin M., Staufenbiel M., Stoeckli M., Wiederhold K.H., Gremlich H.U. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol 2005, 23:577-583.
20. FDG apparatus. J. Label. Compd. Radiopharm 2011, 54:S418.
21. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Price J.C., Reiman E.M., Skovronsky D., Koeppe R.A. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6:221-229. Alzheimer's Disease Neuroimaging Initiative.
22. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh Compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci 2005, 25:10598-10606.
23. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med 2009, 50:818-822.
24. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K., Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med 2007, 48:553-561.
25. Kung H.F., Choi S.R., Qu W., Zhang W., Skovronsky D. 18F stilbenes and styrylpyridines for PET imaging of Aβ plaques in Alzheimer's disease: a miniperspective. J. Med. Chem 2010, 53:933-941.
26. Kuntner C., Kesner A.L., Bauer M., Kremslehner R., Wanek T., Mandler M., Karch R., Stanek J., Wolf T., Müller M., Langer O. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol 2009, 11:236-240.
27. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Kemppainen N., Någren K., Kim B.C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
28. Liu Y., Zhu L., Plössl K., Choi S.R., Qiao H., Sun X., Li S., Zha Z., Kung H.F. Optimization of Automated Radiosynthesis of [18F]AV-45: A new pET imaging agent for Alzheimer's disease. Nucl. Med. Biol 2010, 37:917-925.
29. Lockhart A. Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov. Today 2006, 11:1093-1099.
30. Luo F., Rustay N.R., Ebert U., Hradil V.P., Cole T.B., Llano D.A., Mudd S.R., Zhang Y., Fox G.B., Day M. Characterization of 7-and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol. Aging 2010, 10.1016/j.neurobiolaging.2010.08.005.
31. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci 2007, 27:10957-10968.
32. Mathis C.A., Lopresti B.J., Klunk W.E. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl. Med. Biol 2007, 34:809-822.
33. Matsumura A., Mizokawa S., Tanaka M., Wada Y., Nozaki S., Nakamura F., Shiomi S., Ochi H., Watanabe Y. Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. Neuroimage 2003, 20:2040-2050.
34. Meyer E.P., Ulmann-Schuler A., Staufenbiel M., Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3587-3592.
35. Mirrione M.M., Schiffer W.K., Fowler J.S., Alexoff D.L., Dewey S.L., Tsirka S.E. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 2007, 38:34-42.
36. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol 2009, 66:1469-1475.
37. Niwa K., Kazama K., Younkin S.G., Carlson G.A., Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis 2002, 9:61-68.
38. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci 2006, 26:10129-10140.
39. Okamura N., Mori M., Furumoto S., Yoshikawa T., Harada R., Ito S., Fujikawa Y., Arai H., Yanai K., Kudo Y. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J. Alzheimers Dis 2011, 23:37-48.
40. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego. second ed.
41. Petiet A., Delatour B., Dhenain M. Models of neurodegenerative disease-Alzheimer's anatomical and amyloid plaque imaging. In Vivo NMR Imaging 2011, 293-308. Humana Press, New York, Methods Mol. Biol. 771. L. Schroder, C. Faber (Eds.).
42. Phelps M.E. PET Physics, Instrumentation, and Scanners 2006, Springer Science + Business Media, New York.
43. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jäggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Hölscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940-946.
44. Resnick S.M., Sojkova J., Zhou Y., An Y., Ye W., Holt D.P., Dannals R.F., Mathis C.A., Klunk W.E., Ferrucci L., Kraut M.A., Wong D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PIB. Neurology 2010, 74:807-815.
45. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.
46. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., Tochon-Danguy H., Chan G., Berlangieri S.U., Jones G., Dickinson-Rowe K.L., Kung H.P., Zhang W., Kung M.P., Skovronsky D., Dyrks T., Holl G., Krause S., Friebe M., Lehman L., Lindemann S., Dinkelborg L.M., Masters C.L., Villemagne V.L. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
47. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging β-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
48. Seneca N., Cai L., Liow J.S., Zoghbi S.S., Gladding R.L., Hong J., Pike V.W., Innis R.B. Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for β-amyloid plaques. Nucl. Med. Biol 2007, 34:681-689.
49. Shin J., Lee S.Y., Kim S.H., Kim Y.B., Cho S.J. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008, 43:236-244.
50. Sigurdsson E.M., Wadghiri Y.Z., Mosconi L., Blind J.A., Knudsen E., Asuni A., Scholtzova H., Tsui W.H., Li Y., Sadowski M., Turnbull D.H., de Leon M.J., Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 2008, 29:836-847.
51. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N Engl J. Med 2006, 355:2652-2663.
52. Svedberg M.M., Hall H., Hellström-Lindahl E., Estrada S., Guan Z., Nordberg A., Långström B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int 2009, 54:347-357.
53. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., Galasko D., Praticò D., Griffin S., Schenk D., Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord 2006, 20:6-15.
54. Toyama H., Ye D., Ichise M., Liow J.S., Cai L., Jacobowitz D., Musachio J.L., Hong J., Crescenzo M., Tipre D., Lu J.Q., Zoghbi S., Vines D.C., Seidel J., Katada K., Green M.V., Pike V.W., Cohen R.M., Innis R.B. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:593-600.
55. Ujiie M., Dickstein D.L., Carlow D.A., Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003, 10:463-470.
56. Verhoeff N.P., Wilson A.A., Takeshita S., Trop L., Hussey D., Singh K., Kung H.F., Kung M.P., Houle S. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 2004, 12:584-595.
57. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brasić J.R., Ye W., Hilton J., Lyketsos C., Kung H.F., Joshi A.D., Skovronsky D.M., Pontecorvo M.J. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med 2010, 51:913-920.